- Home
- / OxThera
OxThera
Total Funding
$53.3 M
Revenue
KR11 M
FY, 2015
OxThera Summary
Company Summary
- Overview
- OxThera is a biopharmaceutical company with products in late stage clinical development focusing on Primary and Secondary Hyperoxaluria. OxThera’s intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria, and enzymes. Oxabact® holds Orphan Drug designations in Europe and in the US for the treatment of primary hyperoxaluria.
- Type
- Private
- Status
- Active
- HQ
- Stockholm, SE | view all locations
- Website
- http://www.oxthera.com/
- Cybersecurity rating
Table of Contents
Key People
LocationsView all
2 locations detected
Stockholm, Stockholms län HQ
Sweden
Regeringsgatan 111
Knoxville, TN
United States
245 Crowfield Rd
OxThera Financials
Summary Financials
- Revenue (FY, 2015)
- kr11.0M
- Net income (FY, 2015)
- (kr37.8M)
- Cash (Y, 2015)
- kr8.9M
- EBIT (FY, 2015)
- (kr34.8M)